Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.
Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P, von Pawel J. Reck M, et al. Among authors: eschbach c. Ann Oncol. 2011 Jun;22(6):1374-1381. doi: 10.1093/annonc/mdq618. Epub 2011 Jan 6. Ann Oncol. 2011. PMID: 21212157 Free article. Clinical Trial.
Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.
Scagliotti GV, Ilaria R Jr, Novello S, von Pawel J, Fischer JR, Ermisch S, de Alwis DP, Andrews J, Reck M, Crino L, Eschbach C, Manegold C. Scagliotti GV, et al. Among authors: eschbach c. J Thorac Oncol. 2012 Jun;7(6):1053-7. doi: 10.1097/JTO.0b013e3182519d79. J Thorac Oncol. 2012. PMID: 22588156 Free article. Clinical Trial.
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.
Heigener DF, von Pawel J, Eschbach C, Brune A, Schmittel A, Schmelter T, Reck M, Fischer JR. Heigener DF, et al. Among authors: eschbach c. Lung Cancer. 2013 Jun;80(3):319-25. doi: 10.1016/j.lungcan.2013.02.007. Epub 2013 Mar 20. Lung Cancer. 2013. PMID: 23522488 Clinical Trial.
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, von Pawel J, Ramlau R, Roh JK, Yu CT, Stroh C, Celik I, Schueler A, Pirker R. O'Byrne KJ, et al. Among authors: eschbach c. Lancet Oncol. 2011 Aug;12(8):795-805. doi: 10.1016/S1470-2045(11)70189-9. Epub 2011 Jul 22. Lancet Oncol. 2011. PMID: 21782507
A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M. Schuette WH, et al. Among authors: eschbach c. Clin Lung Cancer. 2013 May;14(3):215-23. doi: 10.1016/j.cllc.2012.10.001. Epub 2013 Jan 16. Clin Lung Cancer. 2013. PMID: 23332288 Clinical Trial.
[Palliative care in respiratory medicine].
Magnussen H, Heigener DF, Bausewein C, Thomas M, Eschbach C, Schütte W, Blankenburg T, Steins M, Bischoff H, Schucher B, Rosseau S, Schütz A, Geiseler J, Kampf S, Karg O. Magnussen H, et al. Among authors: eschbach c. Pneumologie. 2009 May;63(5):289-95. doi: 10.1055/s-0029-1214538. Epub 2009 May 5. Pneumologie. 2009. PMID: 19418389 Free article. Review. German.
43 results